gvtcx

NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin

NHS England Published 30 Jan 2026 Find a Tender
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£37,954,000 (£45,544,800 inc. VAT)
Statuscomplete
Category (CPV) 33600000
RegionNorth East, North West, East Midlands, West Midlands, East of England, South East, South West
Deadline31 Oct 2025
Procedureopen
SME suitableYes
OCIDocds-h6vhtk-05936a

Awards (17)

This procurement was awarded to 9 suppliers. Values shown are per-award; the notice total is £37,954,000.

SupplierValueDateStatus
ACCORD-UK LTD shared £25,881,000 25 Nov 2025 pending
ACCORD-UK LTD shared · · active
AMAROX LIMITED shared · · active
CELIX PHARMA LTD shared £25,881,000 25 Nov 2025 pending
CELIX PHARMA LTD shared · · active
DR REDDY'S LABORATORIES (UK) LIMITED shared £25,881,000 25 Nov 2025 pending
DR REDDY'S LABORATORIES (UK) LIMITED shared · · active
Farmak Pharmaceuticals UK Ltd shared £25,881,000 25 Nov 2025 pending
Farmak Pharmaceuticals UK Ltd shared · · active
GLENMARK PHARMACEUTICALS EUROPE LIMITED shared £25,881,000 25 Nov 2025 pending
GLENMARK PHARMACEUTICALS EUROPE LIMITED shared · · active
TEVA UK LIMITED shared £25,881,000 25 Nov 2025 pending
TEVA UK LIMITED shared · · active
THORNTON & ROSS LIMITED shared £25,881,000 25 Nov 2025 pending
THORNTON & ROSS LIMITED shared · · active
ZENTIVA PHARMA UK LIMITED shared £25,881,000 25 Nov 2025 pending
ZENTIVA PHARMA UK LIMITED shared · · active

description

Project title: NHS National Framework for Transition Products (Apremilast, Pazopanib and Dapagliflozin) commencing 1st February 2026

Offer reference number: CM/TNS/25/5735

Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months.

Potential periods of call-offs under the framework agreement:

CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin

Lot 1 DLN/DNW: 01/02/2026 to 31/01/2027 (12 months)

Lot 2 DLS/DNE: 01/02/2026 to 31/01/2027 (12 months)

Lot 3 DCE/DSW: 01/02/2026 to 30/09/2027 (20 months)

Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

4 notices published against this procurement.

PublishedTypeRegimeNotice
3 Sept 2025 Preliminary market engagement (UK2) Procurement Act 2023 053638-2025
2 Oct 2025 Tender notice (UK4) Procurement Act 2023 061712-2025
26 Nov 2025 Contract award (UK6) Procurement Act 2023 077377-2025
30 Jan 2026 Contract details (UK7) Procurement Act 2023 008310-2026

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.